• Alphamab Oncology received FDA clearance to begin a Phase I trial of JSKN021, its EGFR/HER3-targeting antibody-drug conjugate, in advanced solid tumors.
• The clearance marks the start of overseas clinical development; the China trial dosed its first patient in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261102-12392450), on November 02, 2026, and is solely responsible for the information contained therein.